Relevant bibliographies by topics / Specialized pre-resolving mediators (SPMs)

Academic literature on the topic 'Specialized pre-resolving mediators (SPMs)'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Specialized pre-resolving mediators (SPMs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Specialized pre-resolving mediators (SPMs)"

1

Kraft, Jamie D., Robert Blomgran, Iben Lundgaard, Marianne Quiding-Järbrink, Jonathan S. Bromberg, and Emma Börgeson. "Specialized Pro-Resolving Mediators and the Lymphatic System." International Journal of Molecular Sciences 22, no. 5 (March 9, 2021): 2750. http://dx.doi.org/10.3390/ijms22052750.

Full text
Abstract:
Diminished lymphatic function and abnormal morphology are common in chronic inflammatory diseases. Recent studies are investigating whether it is possible to target chronic inflammation by promoting resolution of inflammation, in order to enhance lymphatic function and attenuate disease. Resolution of inflammation is an active process regulated by bioactive lipids known as specialized pro-resolving mediators (SPMs). SPMs can modulate leukocyte migration and function, alter cytokine/chemokine release, modify autophagy, among other immune-related activities. Here, we summarize the role of the lymphatics in resolution of inflammation and lymphatic impairment in chronic inflammatory diseases. Furthermore, we discuss the current literature describing the connection between SPMs and the lymphatics, and the possibility of targeting the lymphatics with innovative SPM therapy to promote resolution of inflammation and mitigate disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Gila-Diaz, Andrea, Gloria Herranz Carrillo, Pratibha Singh, and David Ramiro-Cortijo. "Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases." Antioxidants 10, no. 6 (June 8, 2021): 933. http://dx.doi.org/10.3390/antiox10060933.

Full text
Abstract:
Cardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolving the inflammation and tissue repair. In addition, SPMs also have anti-inflammatory properties. These physiological effects depend on the availability of LCPUFAs precursors and cellular metabolic balance. Most of the studies have focused on the impact of SPMs in adult cardiovascular health and diseases. In this review, we discuss LCPUFAs metabolism, SPMs, and their potential effect on cardiovascular health and diseases primarily focusing in neonates. A better understanding of the role of these SPMs in cardiovascular health and diseases in neonates could lead to the development of novel therapeutic approaches in cardiovascular dysfunction.
APA, Harvard, Vancouver, ISO, and other styles
3

Chiang, Nan, and Charles N. Serhan. "Specialized pro-resolving mediator network: an update on production and actions." Essays in Biochemistry 64, no. 3 (September 2020): 443–62. http://dx.doi.org/10.1042/ebc20200018.

Full text
Abstract:
Abstract Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2–3 years from human and preclinical animal studies, together with the structural–functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.
APA, Harvard, Vancouver, ISO, and other styles
4

Díaz del Campo, Lucía Serrano, Raquel Rodrigues-Díez, Mercedes Salaices, Ana M. Briones, and Ana B. García-Redondo. "Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling." International Journal of Molecular Sciences 23, no. 7 (March 25, 2022): 3592. http://dx.doi.org/10.3390/ijms23073592.

Full text
Abstract:
Vascular remodeling is a typical feature of vascular diseases, such as atherosclerosis, aneurysms or restenosis. Excessive inflammation is a key mechanism underlying vascular remodeling via the modulation of vascular fibrosis, phenotype and function. Recent evidence suggests that not only augmented inflammation but unresolved inflammation might also contribute to different aspects of vascular diseases. Resolution of inflammation is mediated by a family of specialized pro-resolving mediators (SPMs) that limit immune cell infiltration and initiate tissue repair mechanisms. SPMs (lipoxins, resolvins, protectins, maresins) are generated from essential polyunsaturated fatty acids. Synthases and receptors for SPMs were initially described in immune cells, but they are also present in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), where they regulate processes important for vascular physiology, such as EC activation and VSMC phenotype. Evidence from genetic models targeting SPM pathways and pharmacological supplementation with SPMs have demonstrated that these mediators may play a protective role against the development of vascular remodeling in atherosclerosis, aneurysms and restenosis. This review focuses on the latest advances in understanding the role of SPMs in vascular cells and their therapeutic effects in the vascular remodeling associated with different cardiovascular diseases.
APA, Harvard, Vancouver, ISO, and other styles
5

Valente, Mariarosaria, Marta Dentoni, Fabrizio Bellizzi, Fedra Kuris, and Gian Luigi Gigli. "Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications." Molecules 27, no. 15 (July 28, 2022): 4836. http://dx.doi.org/10.3390/molecules27154836.

Full text
Abstract:
Specialized pro-resolving mediators (SPMs) are lipid mediators derived from poly-unsaturated fatty acids (PUFAs) which have been demonstrated to have an important role in the inflammation environment, preventing an overreaction of the organism and promoting the resolution of inflammation. Our purpose was to point out the current evidence for specialized pro-resolving mediators, focusing on their role in neuroinflammation and in major neurological diseases.
APA, Harvard, Vancouver, ISO, and other styles
6

Chávez-Castillo, Mervin, Ángel Ortega, Lorena Cudris-Torres, Pablo Duran, Milagros Rojas, Alexander Manzano, Bermary Garrido, et al. "Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?" International Journal of Molecular Sciences 22, no. 19 (September 26, 2021): 10370. http://dx.doi.org/10.3390/ijms221910370.

Full text
Abstract:
Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.
APA, Harvard, Vancouver, ISO, and other styles
7

Kytikova, Oxana, Tatyana Novgorodtseva, Yulia Denisenko, Marina Antonyuk, and Tatyana Gvozdenko. "Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma." Medicina 55, no. 6 (June 18, 2019): 284. http://dx.doi.org/10.3390/medicina55060284.

Full text
Abstract:
Asthma is one of the most important medical and social problems of our time due to the prevalence and the complexity of its treatment. Chronic inflammation that is characteristic of asthma is accompanied by bronchial obstruction, which involves various lipid mediators produced from n-6 and n-3 polyunsaturated fatty acids (PUFAs). The review is devoted to modern ideas about the PUFA metabolites—eicosanoids (leukotrienes, prostaglandins, thromboxanes) and specialized pro-resolving lipid mediators (SPMs) maresins, lipoxins, resolvins, protectins. The latest advances in clinical lipidomics for identifying and disclosing the mechanism of synthesis and the biological action of SPMs have been given. The current views on the peculiarities of the inflammatory reaction in asthma and the role of highly specialized metabolites of arachidonic, eicosapentaenoic and docosahexaenoic acids in this process have been described. The possibility of using SPMs as therapeutic agents aimed at controlling the resolution of inflammation in asthma is discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Regidor, Pedro-Antonio, Xavier de la Rosa, Anna Müller, Manuela Mayr, Fernando Gonzalez Santos, Rafael Gracia Banzo, and Jose Miguel Rizo. "PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs)." Biomedicines 10, no. 2 (February 16, 2022): 456. http://dx.doi.org/10.3390/biomedicines10020456.

Full text
Abstract:
Introduction: Polycystic ovary syndrome (PCOS) is an endocrinological disorder that affects 5–15% of women of their reproductive age and is a frequent cause of infertility. Major symptoms include hyperandrogenism, ovulatory dysfunction, and often obesity and/or insulin resistance. PCOS also represents a state of chronic low-grade inflammation that is closely interlinked with the metabolic features. “Classical” pro-inflammatory lipid mediators such as prostaglandins (PG), leukotrienes (LT), or thromboxanes (TX) are derived from arachidonic acid (AA) and are crucial for the initial response. Resolution processes are driven by four families of so-called specialized pro-resolving mediators (SPMs): resolvins, maresins, lipoxins, and protectins. The study aimed to establish lipid mediator profiles of PCOS patients compared to healthy women to identify differences in their resolutive and pro-inflammatory lipid parameters. Material and Methods: Fifteen female patients (18–45 years) were diagnosed with PCOS according to Rotterdam criteria, and five healthy women, as a comparator group, were recruited for the study. The main outcome measures were: pro-inflammatory lipid mediators (PG, LT, TX) and their precursor AA, SPMs (resolvins, maresins, protectins, lipoxins), their precursors EPA, DHA, DPA, and their active biosynthesis pathway intermediates (18-HEPE, 17-HDHA, 14-HDHA). Results: The level of pro-inflammatory parameters in serum was significantly higher in PCOS-affected women. The ratio (sum of pro-inflammatory molecules)/(sum of SPMs plus hydroxylated intermediates) reflecting the inflammatory state was significantly lower in the group of healthy women. Conclusion: There is a strong pro-inflammatory state in PCOS patients. Further research will clarify whether supplementation with SPMs or their precursors may improve this state.
APA, Harvard, Vancouver, ISO, and other styles
9

Thornton, Julianne M., and Kingsley Yin. "Role of Specialized Pro-Resolving Mediators in Modifying Host Defense and Decreasing Bacterial Virulence." Molecules 26, no. 22 (November 18, 2021): 6970. http://dx.doi.org/10.3390/molecules26226970.

Full text
Abstract:
Bacterial infection activates the innate immune system as part of the host’s defense against invading pathogens. Host response to bacterial pathogens includes leukocyte activation, inflammatory mediator release, phagocytosis, and killing of bacteria. An appropriate host response requires resolution. The resolution phase involves attenuation of neutrophil migration, neutrophil apoptosis, macrophage recruitment, increased phagocytosis, efferocytosis of apoptotic neutrophils, and tissue repair. Specialized Pro-resolving Mediators (SPMs) are bioactive fatty acids that were shown to be highly effective in promoting resolution of infectious inflammation and survival in several models of infection. In this review, we provide insight into the role of SPMs in active host defense mechanisms for bacterial clearance including a new mechanism of action in which an SPM acts directly to reduce bacterial virulence.
APA, Harvard, Vancouver, ISO, and other styles
10

Merularini, Saravanan, Madhuram Krishnamurthy, Ashok Leburu, Praveen Nehrudas, Selvendran K. Elangovan, and Naveen Kumar Venugopal. "Specialized pro-resolving lipid mediators: A future for conventional endodontics-A review." IP Indian Journal of Conservative and Endodontics 7, no. 3 (October 15, 2022): 105–8. http://dx.doi.org/10.18231/j.ijce.2022.023.

Full text
Abstract:
Human dental pulp is a highly dynamic tissue that plays major roles in the defense against pathogens and during tissue injury. However, the efficiency of these mechanisms during dental pulp inflammation (pulpitis) varies due to anatomical and physiological restrictions. Uncontrolled progressive unresolved inflammation can lead to pulp tissue necrosis and subsequent apical periodontitis or it can develop into chronic inflammation and become a silent killer causing bone destruction. Considering the cause & effect model, the decision to perform pulp extirpation and endodontic treatment is justifiable only by the lack of therapeutic tools that limit the immune/inflammatory process. The resolution of acute inflammation is necessary to avoid the development of chronic inflammation and to promote repair or regeneration. This active process is orchestrated by Specialized Pro-resolving lipid Mediators (SPMs), which include several families of distinct local mediators (lipoxins, resolvins, protectins and Maresins). These immunoresolvents are distinct from immunosuppressive molecules as they not only dampen inflammation but also promote host defense. Experimental application of SPMs has shown promising result in wide range of inflammatory diseases. This article illustrates about the potential use of SPMs in dentistry
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "Specialized pre-resolving mediators (SPMs)"

1

Davis-Porada, Julia, Charles Serhan, Paul Norris, Peter Lipsky, and Jane E. Salmon. "THU0279 POLYUNSATURATED FATTY ACIDS (PUFAS) AND SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS) ARE DECREASED IN PLASMA AND SERUM FROM SLE PATIENTS COMPARED TO HEALTHY CONTROLS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.2126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Davis-Porada, Julia, Charles Serhan, Paul Norris, Peter Lipsky, and Jane Salmon. "3 Polyunsaturated fatty acids (PUFAs) and specialized pro-resolving mediators (SPMs) are decreased in plasma and serum from SLE patients compared to healthy controls." In 13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019), San Francisco, California, USA, April 5–8, 2019, Abstract Presentations. Lupus Foundation of America, 2019. http://dx.doi.org/10.1136/lupus-2019-lsm.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Specialized pre-resolving mediators (SPMs)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography